Q3 2025 Financials and Cash Runway

Income Statement Snapshot (Quarter ended 30 September 2025)

*Q3 G&A includes a reversal of approximately $3.3M of sublease income from related-party GeneFab that is now considered not collectible.

Balance Sheet (30 September 2025)

Cash Burn and Going Concern

• Cash used in 9M 2025: approximately $36M (from $48.3M to $12.2M).
• Average monthly burn: roughly $4.0M.
• Estimated runway: about 3 months from the Q3 balance sheet date, assuming unchanged burn and no new capital.
• Going concern disclosure: management explicitly states that, without new financing, there is substantial doubt about Senti’s ability to continue as a going concern beyond the near term.

SENTI-202 – ASH 2025 Phase 1 Data in R/R AML

Efficacy Outcomes (18 evaluable patients, R/R AML)

Patient population: relapsed / refractory AML, heavily pre-treated, with CD33 / FLT3 expression. These are patients with very limited options and historically poor outcomes.

Safety Profile

• Cytokine release syndrome (CRS): reported at lower rates and generally lower grade than typical autologous CAR-T programmes.
• Neurotoxicity: no major neurotoxicity signal highlighted in available summaries.
• Haematologic toxicity: present and expected in this population, but described as manageable, with the logic-gate design intended to spare healthy cells.

FDA Designations (2025)

1. Orphan Drug Designation (June 2025) for treatment of AML – providing seven years of market exclusivity in the US if approved.
2. RMAT Designation (9 December 2025) – unlocking access to intensive FDA guidance, potential priority review and the option for accelerated approval on the basis of surrogate endpoints if supported by data.

Together, Orphan + RMAT confirm that the FDA sees SENTI-202 as addressing a serious unmet need with preliminary clinical evidence that may be reasonably likely to predict clinical benefit, and they can materially shorten the regulatory path if later-stage data hold up.

Corporate Timeline and Upcoming Catalysts

Key Milestones

Forward Looking 2026+

• Q1 2026: critical window for securing additional capital (equity, debt, partnerships or non-dilutive funding) to avoid liquidity stress.
• 2026: potential launch of a larger, possibly registrational-intended Phase 2 / 3 programme in AML if funding is secured and RMAT discussions are favourable.
• Beyond 2026: possible indication expansion into paediatric AML, MDS and newly diagnosed segments if the platform proves robust and safety remains acceptable.

Management and Governance

CEO – Timothy Lu, M.D., Ph.D.

Dr. Timothy Lu is a physician-scientist and MIT professor widely recognised as one of the early leaders in synthetic biology and gene-circuit engineering.

• Education: M.D. from Harvard Medical School; Ph.D. in Electrical and Biomedical Engineering from MIT (HST Programme); B.S. and M.Eng. from MIT.
• Academic roles: Professor of Biological Engineering and Electrical Engineering & Computer Science at MIT since 2010.
• Entrepreneurial footprint: Co-founder of multiple biotech companies, including BiomX, Tango Therapeutics, Synlogic and Eligo Bioscience.
• Awards: NIH New Innovator Award; US Presidential Early Career Award for Scientists and Engineers; MIT Technology Review TR35; Navy and Army young investigator prizes.

Compensation levels and equity ownership for Dr. Lu are detailed in Senti’s proxy filings; overall, insiders and long-term institutional holders together represent a meaningful, but not controlling, share of the capital structure.

Ownership and Institutions

• Institutional investors include multiple specialised healthcare funds and generalist asset managers; several have increased or adjusted positions during 2024–2025 as SENTI-202 data evolved.
• Insiders, including founders and early backers, continue to hold significant equity exposure, aligning incentives with long-term value creation, but also concentrating risk.

In short: scientific leadership is best-in-class for synthetic biology, but the company remains small and execution-constrained, with financing risk sitting largely outside the scientific team’s control.

Street View, Targets and Retail Sentiment

Analyst Coverage (late 2025)

Across sources tracking consensus (TipRanks, TickerNerd, Investing.com and others), SNTI shows a cluster of Buy / Outperform ratings with average targets in the high single-digit to low double-digit range (approximately $9–12). That implies several hundred percent upside from pre-ASH trading levels, but is highly sensitive to assumptions around:

• Probability of success for SENTI-202 in later-stage trials.
• Cost and structure of future financings.
• Potential partnerships or other non-dilutive deals.

Retail and Social Sentiment

On Reddit, Stocktwits and X, sentiment into and immediately after ASH was broadly bullish on the data quality, with frequent comparisons to earlier spikes (for example the December 2024 move from roughly $2 to the mid-teens on thin volume). Many traders emphasise:

• The quality of the scientific leadership and the logic-gated CAR-NK concept.
• The fact that all reported CRs to date are MRD-negative.
• The Orphan + RMAT designation combination as a strong external validation signal.

At the same time, retail discussion also surfaces the critical going-concern language, the tiny float (around 6–7M shares) and the high probability of substantial near-term dilution. This mix creates a fertile environment for sharp squeezes and equally sharp reversals.

Competitive Landscape – CAR-NK / CAR-T in AML and Beyond

Senti operates in a crowded and rapidly evolving space. Multiple companies are developing allogeneic CAR-NK or related platforms, although most approved therapies today remain autologous CAR-T products for B-cell malignancies.

Positioning of SENTI-202

• Logic gating: SENTI-202 uses dual targeting (CD33 / FLT3) and gene-circuit logic to refine tumour versus healthy cell recognition and reduce on-target / off-tumour toxicity.
• Allogeneic CAR-NK: Off-the-shelf design removes the need for patient-specific manufacturing and may improve scalability and time-to-treatment.
• Engineered IL-15: The construct is designed to support persistence and expansion without excessive cytokine toxicity.
• Safety: Early safety looks encouraging compared with many first-generation CAR-T attempts in AML, though the dataset is still small.

Benchmarking against published CAR-T data in AML (for example CD123 and CLL-1 programmes), SENTI-202’s early complete remission rates in a small Phase 1 cohort are broadly in line with the lower end of reported CR ranges, but with the added benefits of MRD-negative responses and an allogeneic NK backbone. Whether this will translate into durable, commercially relevant outcomes in a larger Phase 2/3 setting remains an open question.

Valuation, Multiples and Key Risks

High-Level Valuation Snapshot (9 Dec 2025)

• Market capitalisation: roughly $63M at $2.84 after-hours.
• Enterprise value: approximately $51M (market cap minus Q3 cash of $12.2M, ignoring other balance-sheet complexities).
• Revenue: none; the company is fully pre-revenue.
• Book value: stockholders’ equity of ~$8.1M; price / book ratio therefore elevated versus typical micro-cap peers.

Compared with other clinical-stage micro-cap biotech names, SNTI trades at a modest absolute valuation but at a rich multiple of book value, reflecting:

• Platform optionality and the perceived quality of the technology / team.
• The positive Phase 1 data and RMAT status for SENTI-202.
• The fact that equity markets are already pricing in additional dilution.

Critical Risks

1. Financing / Going Concern (immediate)

• Runway of roughly three months from the Q3 balance sheet date, assuming similar burn.
• Explicit “substantial doubt” going-concern language in SEC filings.
• High probability of a sizeable equity raise, potential reverse split or both, if no strategic deal is signed.
• Impact: very high – this is the dominant near-term risk.

2. Clinical and Regulatory Risk

• Data so far are based on a small Phase 1 cohort (18 evaluable patients).
• Durability of response (7.6-month median composite CR) is encouraging but still immature.
• AML has historically been a difficult graveyard for CAR-based therapies due to antigen heterogeneity and an immunosuppressive microenvironment.
• Impact: moderate to high – binary around future trials.

3. Operational and Execution Risk

• Senti is a very small organisation attempting to run complex cell-therapy trials while also maintaining a broad platform roadmap.
• Manufacturing reliability, scale-up and quality-control will be central to regulatory success and commercial viability.
• Volatility is structurally high given a thin float and speculative retail participation.
• Impact: moderate – can amplify both upside and downside.

Illustrative Scenarios (Not Investment Advice)

The following scenarios are illustrative only, based on public information and typical ranges observed in similar stories. They are not price targets or recommendations and should not be used as the basis for any investment decision.

Bull Case – Platform Success and Non-Destructive Financing (approx. probability: 35%)

• Company secures a sizeable strategic or non-dilutive financing (for example, partnership or structured deal) that extends runway through key milestones.
• Phase 2 data confirm ORR above 50%, durable CRs and an acceptable safety profile.
• RMAT pathway leads to an accelerated approval filing around 2027–2028.
• Equity markets reward both SENTI-202 and the broader gene-circuit platform.
• Illustrative equity value range: share price could plausibly reach the low-double-digit range ($10–15) over several years if the thesis plays out.

Base Case – Dilution + Ongoing Development (approx. probability: 40%)

• Company raises equity in Q1 2026 with 30–50% dilution at depressed prices.
• SENTI-202 progresses into a larger Phase 2; data remain positive but not clearly transformative; timelines stretch.
• Some form of co-development or regional partnership is secured later in 2026–2027.
• Illustrative equity value range: share price oscillates in a band somewhere in the mid-single to high-single digits ($5–8), with high volatility.

Bear Case – Funding Shortfall or Disappointing Data (approx. probability: 25%)

• No credible financing arrives in time, forcing extreme dilution, asset sales or formal restructuring.
• Alternatively, larger studies show lower efficacy or emerging safety signals.
• Platform perception deteriorates; strategic interest fades.
• Illustrative equity value range: share price could fall into the sub-dollar to low-single-digit range ($0.50–1.50) with a real risk of permanent capital loss.

Bottom Line – Facts versus Interpretation

Key Facts (Data-Based)

1. Cash as of 30 September 2025 was $12.2M with roughly $36M consumed over the first nine months of 2025, implying around three months of runway absent new funding.
2. SENTI-202 delivered a 50% ORR and 42% CR/CRh at RP2D in R/R AML at ASH 2025, with all reported CRs MRD-negative and a 7.6-month median duration of composite CR to date.
3. The FDA has granted both Orphan Drug and RMAT designations to SENTI-202 in AML.
4. Street coverage from Chardan Capital, HC Wainwright, Laidlaw and Leerink Partners is currently uniformly positive (Buy / Outperform), with indicative price targets mostly clustered between $5 and $12.
5. There is an explicit going-concern warning in the latest SEC filings, and the company has no commercial revenue.

Interpretation

On the science and data side, SNTI is one of the more interesting small-cap stories in the AML space: logic-gated allogeneic CAR-NK is a credible attempt to solve real problems that have limited the success of earlier CAR-based approaches in myeloid disease, and the initial ASH dataset is not just a “signal” but a set of responses that would be clinically meaningful if reproduced at scale.

On the financial side, however, the company is in a very fragile position. Without a substantial financing or a strategic transaction, the deliberate going-concern language in the Q3 10-Q should be taken at face value. For traders and investors, this means the story is not just about whether SENTI-202 works, but also about when and on what terms Senti can refinance itself.

In practical terms, SNTI is best described as a high-beta, binary platform bet on cutting-edge cell-therapy engineering with a very narrow funding runway. The upside is that a relatively small absolute dollar increase in enterprise value can translate into very large percentage moves; the downside is that failures in funding or data can equally rapidly drive the equity towards zero.

Regulatory Disclaimer (SEC / CONSOB / ESMA)

Authors and Final Note

Authors: Merlintrader and Jane.